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Objective: To evaluate possible associations between cardiovascular autonomic dysfunction and peripheral artery
disease (PAD) in patients with type 2 diabetes mellitus.
Research design and methods: In this cross-sectional study, 67 patients with type 2 diabetes were included. PAD
was identified by Doppler ultrasonography: systolic ankle-brachial pressure index <0.9. Cardiovascular autonomic
function, besides five conventional cardiovascular autonomic function tests, was assessed by heart rate variability
(HRV; 24-h ambulatory ECG recording) in time and frequency domains (spectral analyses) and three dimensional
return maps. Power spectral analyses (PSA) were quantified in low frequency (LF), high frequency (HF), and very
low frequency.
Results: Patients with PAD (n = 30) had longer diabetes duration, higher systolic blood pressure (BP), waist-to-hip
ratio, HbA1C test, and urinary albumin excretion (UAE) than patients without PAD. Most HRV indices in time
domain were lower in patients with than without PAD. These patients also had lower PSA indices (LF=0.19±0.07
vs. 0.29±0.11 n.u.; LF/HF ratio=1.98±0.9 vs. 3.35±1.83; P<0.001) and indices of sympathetic (three-dimensional
return map: P1-night 61.7±9.4 vs. 66.8±9.7; P=0.04) and vagal (24-h P2 54.5±15.2 vs. 62.7±2.9; P< 0.02) activities
(arbitrary units) than patients without PAD. Multivariate logistic regression analyses, adjusted for systolic BP, DM
duration, HbA1C test, and UAE, confirmed the associations between impaired autonomic modulation and PAD,
except for P1 index.
Conclusion: In conclusion, patients with type 2 diabetes with PAD had lower HRV indices than patients without
PAD, reflecting a dysfunction of cardiovascular autonomic modulation.
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Patients with diabetes mellitus have a generalized athero-
sclerosis of the arterial bed, characterized by an early on-
set and a fast progression rate. Diabetes increases the
risk for peripheral arterial disease (PAD) 2- to 3-fold [1].
Moreover, PAD, together with microvascular disease
and peripheral neuropathy, is responsible for the high* Correspondence: luishenriquecanani@gmail.com
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reproduction in any medium, provided the orincidence of non traumatic amputations in patients with
diabetes [1].
Intermittent claudication, the main clinical manifest-
ation of PAD, has been associated with increased mortality
[2]. The lower-extremity arterial calcification that occurs
in PAD has been considered as a correlate of coronary ar-
tery calcification, at least in type 1 diabetes [3]. In patients
with diabetes and PAD, besides the presence of coronary
and cerebral atherosclerosis [4], cardiovascular autonomic
neuropathy (CAN) can partially explain the high rate of
cardiovascular mortality observed [5]. Disturbances in
the autonomic system modulation seem to precede theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Canani et al. Diabetology & Metabolic Syndrome 2013, 5:54 Page 2 of 9
http://www.dmsjournal.com/content/5/1/54increase in the thickness of the carotid intima, a predictor
of atherosclerosis progression in patients with type 2
diabetes [6,7].
CAN has been traditionally diagnosed by cardiovascu-
lar autonomic function tests [8]. CAN can also be evalu-
ated by heart rate variability (HRV) analyses [6], through
the quantification of very small heart rate changes from
one cardiac cycle to the next. This technology enables
quantification of the relative influence of sympathetic and
parasympathetic systems on the sinus node and, com-
pared to conventional cardiovascular autonomic tests, has
a higher sensitivity to detect autonomic abnormalities [9].
HRV detects both instantaneous heart rate and R-R
intervals of the electrocardiogram. It is usually analyzed
in time domain and frequency domain. The latter is also
known as power spectral analysis (PSA). Time domain
indices evaluate the dispersion of the cardiac R-R inter-
vals around the mean, and reflect overall autonomic
modulation on the sinus node. PSA evaluates the vari-
ance of R-R intervals as a function of frequency and is
calculated by mathematical algorithms. The PSA results
exhibits three main components: very low frequency (VLF;
with no clearly defined participation in HRV), low fre-
quency (LF; mainly sympathetic modulation), and high
frequency (HF, parasympathetic modulation). PSA of HRV
has been considered to be a useful tool in assessing the
autonomic nervous system function in patients with dia-
betes [10].
A comprehensive evaluation of the autonomic nervous
system function in diabetic patients with PAD has not
been performed to date. This knowledge may contribute
to earlier diagnosis and intervention in patients at higher
cardiovascular risk in order to decrease the rate of lower
extremity amputations and mortality. Therefore, the aim
of the current study was to evaluate possible associations
of cardiovascular autonomic dysfunction with PAD in
patients with type 2 diabetes.Research design and methods
Subjects
This was a cross-sectional study nested in a prospective
cohort. Patients with type 2 diabetes were selected from
a cohort of consecutive outpatients attending the Endo-
crine Division at Hospital de Clínicas de Porto Alegre.
Details of the original cohort have been previously pub-
lished [11]. From the original cohort of 98 patients with
type 2 diabetes, 84 patients were available for evaluation.
Missing patients (n = 14) did not differ from the included
patients regarding age, diabetes duration, proportion of
females, and ethnicity (data not shown).
The definition of type 2 diabetes was based on age of
onset (>30 years old), no episodes of ketoacidosis and
no need for insulin use during the first five years ofdiagnosis. Patients underwent a clinical and laboratory
evaluation and the Ethics Committee approved the proto-
col. All patients gave written informed consent.
General clinical evaluation
All patients answered a standard questionnaire that in-
cluded questions about age, diabetes duration, smoking
habit (defined as positive if the patient had smoked at
least one cigarette a day for more than one year), and
medications in use. Patients self-identified themselves as
white or non-white (mixed or black). Patients were weighed
in light clothes, without shoes, and height was recorded.
Body mass index (BMI) was calculated as weight (kilo-
grams) divided by squared height (meters). Waist and
hip circumferences were measured with a soft tape in
the upright position, on bare skin at the level the um-
bilicus and iliac crest, during mid-respiration, to the
nearest 0.5 cm. Waist-to-hip ratio was calculated. Blood
pressure (BP) was measured twice, in the sitting position,
after a 10-min rest to the nearest 2 mmHg, using an
aneroid sphygmomanometer. Hypertension was defined
as BP levels ≥140/90 mmHg or the use of antihyperten-
sive medication. Indirect ophthalmoscopy was performed
by an ophthalmologist through dilated pupils and diabetic
retinopathy was classified as present (any degree) or ab-
sent. The diagnosis of ischemic heart disease was based
on the presence of at least one of the following: angina or
possible infarct according to the WHO questionnaire
for cardiovascular disease [12]; resting ECG abnormalities
[Minnesota Codes: Q and QS patterns (1–1 to 1–3); S-T
junction (J) and segment depression (4–1 to 4–4); T-wave
items (5–1 to 5–3), and complete left bundle branch block
(7–1)] [12], and/or perfusion abnormalities on myocardial
scintigraphy at rest (fixed) or after infusion of dipyrid-
amole. Based on their 24-h urinary albumin excretion
(UAE), patients were classified as normoalbuminuric
(<20 μg/min), microalbuminuric (20–199 μg/min) or macro-
albuminuric (>199 μg/min) [13]. Diabetic nephropathy was
diagnosed in the presence of micro- or macroalbuminuria
and was always confirmed in a second urine sample col-
lected over a 3- to 6-month period [13,14]. None of the
patients with diabetic nephropathy had a doubtful etiology
of their kidney disease (e.g. absence of retinopathy, rapid
decline in glomerular filtration rate, resistant hyperten-
sion, or heavy proteinuria) [15]. Patients on angiotensin
conversion enzyme inhibitors or angiotensin receptor
antagonists had their urine samples collected after a
minimum three-weeks interruption of these medications.
The diagnosis of peripheral neuropathy was established
if the Michigan score was greater than 2. This score is
based on foot examination (deformities, callus, infection,
ulceration), ankle reflex response, tactile sensitivity (nor-
mal, reduced or absent) and vibration perception thresh-
old (normal, reduced or absent, 128 MHz tuning fork) at
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tested all participants.
Peripheral artery disease assessment
PAD was accessed by systolic ankle-brachial BP ratio.
The systolic BP was obtained on the ankle (posterior
tibial and/or pedious arteries) and arms (brachial artery)
of both sides, using Doppler ultrasonography [17]. The
systolic BP ratio was calculated by dividing the ankle BP by
the ipsilateral arm BP. PAD was defined by a ratio <0.9 on
any side. Patients were divided into two groups according
to systolic BP ratio values: with and without PAD.
Autonomic nervous system evaluation
Cardiovascular autonomic function test:
The autonomic nervous system was assessed by cardio-
vascular autonomic function tests as validated by Ewing
and co-workers [8], and autonomic neuropathy was di-
agnosed when at least 2 out of 5 tests were abnormal
[8,18]. Potentially interfering drugs were weaned off be-
fore the tests. No subject was on antiarrhythmic agents.
Briefly, heart rate tests were performed with patients
electrocardiographically monitored and heart rate was
evaluated after 15 min of resting, before and after deep
breath, during the Valsalva maneuver, and after standing.
The BP tests evaluated the BP response one minute after
standing up from lying down, and after sustained hand-
grip at 30% of the maximum voluntary contraction cap-
acity, using a handgrip dynamometer.
Heart rate variability: time and frequency domain indices
HRV was also evaluated using ECG recording by the time
domain and frequency domain methods (PSA), as well as
the three dimensional return maps, during the day and
the night periods [10]. The patients received verbal and
written instructions to abstain from alcoholic and caf-
feinated beverages or caffeinated medications, and sys-
temic decongestants, as well as to avoid vigorous exercises
and not to wear elastic stockings from the day before the
test. They were also advised to maintain their usual daily
activities and to answer a questionnaire regarding the
number of cigarettes smoked and any exceptional activ-
ity (extra physical activity or arguing) on the day of
examination. For HRV analyses, ECG tapes were analyzed
on a Mars 8000 (Marquete) scanner with a semiautomatic
technique [10]. This software distinguishes normal beats
from ectopic and artifacts and builds a time series of nor-
mal R-R intervals. Non sinus beats were eliminated and,
for PSA, missing data were interpolated. PSA was com-
puted for periods of 256 s using fast Fourier transform-
ation. Only segments free of interpolations were analyzed.
The following time domain HRV indices were calcu-
lated from 24-h ECG recordings: mean of all R-R inter-
vals, SD of the R-R intervals (SDNN), mean of the SDof R-R intervals calculated in 5-min segments (SDNNi),
SD of averages of R-R intervals calculated in 5-min
segments (SDANNi), root mean square of successive
differences of adjacent R-R intervals (RMSSD), and
percentage of differences between adjacent R-R inter-
vals >50 ms (PNN50). The frequency-domain analyses
were performed at complete rest, with patients lying in
the supine position, in order to avoid loss of station-
arity. During a 5-minute period, the following spectral
components were assessed: total power (0.003-1 Hz),
VLF (<0.04 Hz), LF (0.04-0.15 Hz), HF (0.15-0.5 Hz) and
LF/HF ratio. LF component reflects both sympathetic
and vagal tones, but mostly the sympathetic modulation,
and HF component is closely related to respiratory fre-
quency, reflecting vagal (parasympathetic) sinus node
modulation. The total power and LF/HF ratio, which is
a measure of sympathovagal balance, were calculated
for each patient. The results of LF and HF were reported
in absolute and normalized units (n.u.).
Heart rate variability: three-dimensional return map
The three-dimensional return map, a method based on
nonlinear dynamics, reflects sympathetic and vagal modu-
lation as we demonstrated by autonomic blockade studies
with propranolol and atropine, in a reproducible way [10].
The map is constructed by plotting normal R-R intervals
versus the difference between adjacent R-R intervals ver-
sus counts. Briefly, normal R-R intervals are plotted on
the X-axis against the difference between adjacent R-R
intervals on the Y-axis. Whenever superimposition of
points occurs, the number of superimposed points is
expressed on the Z-axis, normalized by the maximum
density. A set of indices (P1, P2, P3, MN) is calculated to
quantify the resulting three-dimensional images. P1 rep-
resents sympathetic modulation and is increased during
sympathetic blockade with propranolol but is not affected
by the administration of atropine. P1 is calculated as 100
minus the double of the mean slope between 10 and 90%
of maximum density, in the plane that intersects the
distribution in its maximum concentration of points,
perpendicular to normal R-R intervals. P1 is inversely
proportional to the mean slope of the distribution
calculated at the maximum concentration of points. As
concentration of points increase, the slope will be
higher and P1 will be smaller. Therefore, the higher the
sympathetic activity, the lower the value attributed to
P1. P2 and P3 represent vagal modulation, are reduced
during vagal blockade with atropine but are not affected
by the administration of propranolol. To calculate P2
and P3, three-dimensional images are displayed as 10
equally spaced contour curves: P2 is calculated as the
maximal longitudinal length, and P3, as the maximal
transversal length of the outermost contour curve. The
general index MN was calculated as the product of
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-3. MN represents either branches of the
autonomic nervous system being affected by propran-
olol and atropine [10].
The 24-h ambulatory ECG recording and cardiovascu-
lar autonomic function tests were performed in the same
day by the same investigator. Nighttime was recorded as
the period between the time when the patient went to
bed and the time when the patient woke up in the next
morning.
Laboratory evaluation
Urinary albumin excretion rate (UAER) was measured
by immunoturbidimetry (Microalb; Ames-Bayer, Tarrytown,
NY, USA; intra- and interassay coefficients of variations
4.5% and 11.0%, respectively). Glycated hemoglobin (HbA1c
test) was measured by a high performance liquid chro-
matography (HPLC; Merck-Hitachi L-9100 glycatedTable 1 Clinical and laboratory characteristics of type 2 diabet
With PAD
n 24
Systolic ankle-brachial BP index 0.77 ± 0.09
Age (years) 65.8 ± 6.8
Male 12 (50%)
DM duration (years) 20.2 ± 7.1
Smoking 7 (29%)
Body mass index (kg/m2) 30.1 ± 4.6
Waist-to- hip-ratio 0.98 ± 0.09
Diabetes treatment
Oral agents 6 (25%)
Insulin (with or without oral agents) 18 (75%)
Insulin dose (U/day) 46.9 ± 19.8
Hypertension 23 (95%)
Hypertension treatment
ACE inhibitors 4 (16%)
Diuretics 5 (21%)
Calcium channel blockers 10 (42%)
Beta blockers 5 (21%)
Peripheral neuropathy 17 (70%)
Autonomic neuropathy 20 (83%)
Fasting plasma glucose (mg/dl) 210.2 ± 70.
HbA1C test (%) 7.9 ± 1.7
Total cholesterol (mg/dl) 222.6 ± 50.
HDL cholesterol (mg/dl) 46.2 ± 26.9
Triglycerides (mg/dl) 164.5 (812)
Serum creatinine (mg/dl) 1.1 ± 0.4
24-h UAE (μg/min) 90.3 (5560)
Data expressed as mean ± SD, median (range), or number of patients with the charact
Autonomic neuropathy: defined according to conventional autonomic cardiovascular f
U test; δ Chi-square test.hemoglobin analyzer, reference range 4.7-6.0%; Merck
Diagnostica, Darmstadt, Germany), fasting plasma glu-
cose was measured by glucose-peroxidase colorimetric
enzymatic method (Biodiagnostica, São Paulo, Brazil).
Creatinine was measured by the Jaffé method and the
lipid profile by a colorimetric method. Glomerular
filtration rate was measured in 67 patients using the
single-injection 51CrEDTA technique (coefficient of
variation = 12%) [19].
Statistical analyses
Variables are described as means ± standard deviation
(variables with normal distribution), as median (range)
(variables without normal distribution) and as the number
of patients with the analyzed characteristic (percentage).
Student’s t-test was used for continuous, normally distrib-
uted variables; Mann-Whitney’s U test was employed foric patients and the presence of peripheral arterial disease
Without PAD P
43 -
0.98 ± 0.07 -
63.2 ± 8.3 0.189*
16 (37%) 0.309δ
15.2 ± 7.9 0.008*
10 (23%) 0.632δ
29.7 ± 4.8 0.773*
0.93 ± 0.08 0.059*
20 (46%) 0.083δ
23 (53%) 0.083δ








5 176.3 ± 70.3 0.063*
6.7 ± 1.6 0.010*
9 214.6 ± 45.2 0.511*
45.6 ± 10 0.896*
134 (400) 0.097#
1.1 ± 0.9 0.858*
8.7 (2345) 0.000#
eristic (%); PAD = peripheral arterial disease: BP = blood pressure.
unction tests: two out five abnormal tests [8]. *Student’s t-test; # Mann-Whitney’s
Table 2 Heart rate variability analyses in time domain
according to the presence of peripheral vascular disease
With PAD Without PAD P*
n 24 43 -
Mean RR 24-h (ms) 767 ± 79 776 ± 92 0.98
Mean RR day (ms) 652 ± 263 738 ± 145 0.55
Mean RR night (ms) 811 ± 99 841 ± 93 0.41
SDNN 24-h (ms) 87 ± 35 105 ± 27 0.009
SDNN day (ms) 75.7 ± 34.2 92 ± 30,7 0.001
SDNN night (ms) 82.2 ± 39.1 96 ± 33.5 0.002
SDANN 24-h (ms) 3.54 ± 6.33 3.95 ± 5.6 0.16
SDANN day (ms) 3.42 ± 6.43 3.81 ± 0.6.3 0.02
SDANN night (ms) 3.86 ± 7.08 5.16 ± 7.7 0.13
SDNNi 24-h (ms) 18.4 ± 11.4 21.3 ± 12.9 0.002
SDNNi day (ms) 17.6 ± 11.7 20.1 ± 12.1 0.001
SDNNi night (ms) 19.7 ± 11.7 81.9 ± 37.5 0.004
RMSSD 24-h(ms) 28.5 ± 11.8 38.3 ± 13.7 0.16
RMSSD day (ms) 27.3 ± 11.3 36.9 ± 13.8 0.21
RMSSD night (ms) 30.6 ± 14.2 42.2 ± 16.1 0.15
PNN50 24-h (%) 76.4 ± 29.3 87.8 ± 25.9 0.19
PNN50 day (%) 63.4 ± 29.9 76.7 ± 26.6 0.23
PNN50 night (%) 67.7 ± 31.5 73.0 ± 27.5 0.22
Data were log transformed before analyses and then expressed as mean ± SD.
PAD = peripheral arterial disease; SDNN = SD of the R-R intervals, SDNNi = mean
of the SD of R-R intervals calculated in 5-min segments, SDANNi = SD of the
averages of the R-R intervals calculated in 5-min segments; RMSSD = root mean
square of successive differences of adjacent R-R intervals; (PNN50) = percentage
of differences between adjacent R-R intervals >50 ms;
* Student’s t-test.
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chi-square test was used for categorical variables. There
are no clearly established cutoff points to identify normal/
abnomal values for some HRV indices. Therefore, we
decided to categorize HRV indices according to their
tertiles, based on studied sample values. This approach
allows the identification of differences between groups
since the lowest tertile for HRV indices should include
the most abnormal values associated with CAN. To evalu-
ate if the HRV indices (independent variables) were asso-
ciated with PAD (dependent variable), multivariate logistic
regression analyses were performed, adjusted for potential
confounders. In these models, heart rate variability indices
were categorized by tertiles and the upper (3rd) for each
index was considered as the reference (OR = 1). HRV in-
dices were log-transformed before analyses. P values <0.05
(two-tailed) were considered statistically significant. Statis-
tical analyses were performed using SPSS 18.0 (SPSS,
Chicago, IL).
Results
Evaluation of CAN by HRV analyses was available in
67 out of 84 studied patients. The reasons for the ex-
clusion from the protocol were as follows: incomplete
tests (n = 10), presence of more than 10% of cardiac
ectopic beatings on 24 h-ECG records, or cardiac arrhyth-
mias that preclude the HRV analyses (n = 7). Frequency
of PAD in the included patients was not different from
all studied patients (35.8% vs. 35.7%; P = 0.881).
Clinical and laboratory characteristics of the 67 patients
with and without PAD are depicted in Table 1. Patients
with PAD had longer diabetes duration, higher waist-
hip-ratio, and history of hypertension than those without
PAD. Diabetic chronic complications, including auto-
nomic neuropathy as evaluated by conventional cardio-
vascular autonomic function tests, were more frequent
in patients with PAD as compared with patients without
PAD. Regarding laboratory variables, the PAD group
had a worse glycemic control and higher UAE than the
group without PAD. There was no difference in diabetes
treatment between patients with and without PAD.
Heart rate variability: time domain indices
Regarding to time domain indices, patients with PAD
had lower SDNN and SDNNi, at 24-h, day and night,
and SDANN during the day as compared to patients
without PAD (Table 2). Figure 1A shows the prevalence
of PAD within each tertile for individual time domain
indexes. PAD was more frequent in the 1st tertile of SDNN
during the day and of SDNNi at 24-h, day, and nigh.
Heart rate variability: frequency domain indices
In the analyses of HRV in frequency domain (Table 3),
total spectral power, VLF, LF and HF components, werelower in patients with PAD as compared to patients with-
out PAD. Figure 1B shows the frequency of PAD within
each tertile for individual PSA indices. PAD was more
frequent in the 1st tertile of LF, HF and LF/HF ratio.
Heart rate variability: three-dimensional return map
The three dimensional return map data (Table 3) shows
sympathetic (P1), vagal (P2 and P3) and global modula-
tion (MN) during the 24-h, day, and night periods. P1
was lower during the night and P2 was lower at all pe-
riods in patients with PAD in comparison with those
without PAD. When P1 and P2 were stratified into tertiles,
patients in the lowest tertiles had the highest frequency
of PAD (Figure 1C).
Multivariate analyses
Logistic regression analyses were performed to evaluate
the association of PAD (dependent variable) with tertiles
of HRV indices, taken into account possible confounders,
namely, diabetes duration, glycemic control, triglycerides,
and UAE (Table 4). The 1st tertile of SDNN at day and
SDNNi at night increased the chance of PAD being
















































Figure 1 Prevalence of peripheral artery disease according to autonomic neuropathy. Prevalence of peripheral artery disease within each tertile
for individual time domain indices (A), power spectral analyses indices (B), and Three Dimensional Return Map data (C). Black bar represents first tertile,
gray bar second tertile, and white bar third tertile. P<0.05 for all comparisons.
Canani et al. Diabetology & Metabolic Syndrome 2013, 5:54 Page 6 of 9
http://www.dmsjournal.com/content/5/1/54(CI 95% 1.6-37.3; P = 0.012), respectively. Having a high
frequency index or a low frequency index in the lowest
tertiles respectively raised the chance of PAD 7.37 times(CI 95% 1.5-37.3; P = 0.016) and 6.17 times (CI 95%
1.1-35.1; P = 0.04). The 1st tertile of HF/LF ratio was also
associated with an increased chance for the presence of
Table 3 Heart rate variability analyses in frequency domain
(power spectral analyses) and three dimensional return
map data of type 2 diabetic patients according to
peripheral arterial disease
With PAD Without PAD P*
n = 24 N = 43
Power spectral analyses #
Very low frequency ms2/Hz 328 ± 295 755 ± 924 0.032
Low Frequency ms2/Hz 123 ± 152 490 ± 815 0.01
High Frequency ms2/Hz 61 ± 85 137 ± 162 0.005
Total Power ms2/Hz 538 ± 513 1406 ± 1880 0.031
Low frequency (LF) n.u. 0.55 ± 0.13 0.75 ± 0.42 0.56
High frequency (HF) n.u. 0.31 ± 0.06 0.25 ± 0.14 0.46
Low frequency/ High frequency 1.98 ± 0.9 3.37 ± 1.82 0.067
Three dimensional return map
P1 24-h 59.5 ± 9.5 61.6 ± 8.7 0.38
P1 day 58.0 ± 9.5 61.0 ± 7.7 0.17
P1 night 61.7 ± 9.4 66.8 ± 9.7 0.04
P2 24-h 54.5 ± 15.2 62.7± 2.9 0.02
P2 day 46.5 ± 13.6 54.9 ± 12.7 0.01
P2 night 44.5 ± 14.5 51.9 ± 12.7 0.03
P3 24-h 75.0 ± 37.1 80.3 ± 30.8 0.52
P3 day 65.4 ± 33.7 72.5 ± 30.3 0.37
P3 night 61.4 ± 24 65.6 ± 23 0.47
MN 24-h 272 ± 227 326 ± 195 0.31
MN Day 195 ± 156 259 ± 182 0.15
MN night 186 ± 136 247 ± 135 0.08
Data expressed as mean ± SD; P1 = index reflecting sympathetic modulation;
P1, P2, and P3 are expressed as arbitrary units; P2 and P3 = indices reflecting
vagal modulation; MN = global modulation; * Student t-test; # Data were log
transformed before analyses.
Table 4 Multivariate logistic regression analyses: heart rate
variability indices (independent variables) categorized by
tertiles and their respective odds ratios for the presence of
peripheral arterial disease (dependent variable)
Odd ratio* 95%CI P
Time domain indices
SDNN day
1st tertile 6.08 1.24 - 29.90 0.026
2nd tertile 0.80 0.20 - 3.90 0.784
3rd tertile 1.0 - -
SDNNi night
1st tertile 7.67 1.60 - 37.30 0.012
2nd tertile 1.14 0.20 - 6.20 0.878
3rd tertile 1.00 - -
Frequency domain indices
High Frequency
1st tertile 7.37 1.50 - 37.30 0.016
2nd tertile 5.16 0.90 - 30.00 0.068
3rd tertile 1.00 - -
Low Frequency
1st tertile 6.17 1.10 - 35.10 0.040
2nd tertile 4.00 0.70 - 24.40 0.129
3rd tertile 1.00 - -
High Frequency / Low Frequency Ratio
1st tertile 7.42 1.50 - 37.10 0.015
2nd tertile 2.01 0.40 - 11.30 0.392
3rd tertile 1,00 - -
Tridimensional return map
P1 night
1st tertile 2.67 0.60 - 11.80 0.195
2nd tertile 0.73 0.10 – 4.10 0.720
3rd tertile 1.00 - -
P2 day
1st tertile 8.42 1.50 - 47.50 0.016
2nd tertile 2.59 0.40 - 15.90 0.305
3rd tertile 1.00 - -
* the odds ratio was adjusted for diabetes duration, HbA1C, hypertension,
serum triglycerides, and urinary albumin excretion in each model. SDNN= SD
of the R-R intervals; SDNNi = mean of the SD of R-R intervals calculated in
5-min segment; P1 = index reflecting sympathetic modulation; P2 = index
reflecting vagal modulation; upper index tertile (3rd) for each index was
considered as the reference (OR = 1).
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the three dimensional return maps analyses, only a daily
vagal modulation index (P2) in the lowest tertile in-
creased the chance for PAD 8.42 times (CI 95% 1.5-47.5;
P = 0.016). To take into account a possible effect of
fasting plama glucose (FPG) at the start of the test, the
same multivariate logistic regression analyses models were
performed including FPG instead of HbA1C. No signifi-
cant differences were observed in the main results (data
not shown).Discussion
In this sample of patients with type 2 diabetes, PAD was
associated with autonomic neuropathy, as evaluated both
by conventional cardiovascular autonomic function tests
and HRV indices. This association remained even after
adjustments for glycemic control, triglycerides, hyper-
tension, diabetes duration, and UAE. Moreover, theHRV analyses allowed the evaluation of sympathetic/
parasympathetic balance in these patients.
The association of autonomic nervous system with PAD
was confirmed in the multivariate analyses for some of
the time domain indices and frequency domain indices
including the HF/LF ratio. This means that there was
an abnormal modulation of both vagal and sympathetic
systems. Although the role of time and frequency domain
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tem has been widely debated, autonomic blockade studies
confirm that these indices represent mostly vagal modula-
tion of the sinus node [20]. Furthermore, in the multivari-
ate analyses only the daily P2 index, which represents the
parasympathetic component of HRV, was associated with
PAD. In summary, we demonstrated an association of PAD
and abnormal autonomic nervous system and our data sug-
gest that the most affected branch was the parasympathetic.
In the current study, day and night periods were ana-
lyzed separately. In normal subjects there is a circadian
pattern of heart rate autonomic modulation with a re-
duced HRV during the day, secondary to increased sym-
pathetic activity, and an increased HRV during the night
due to the predominance of vagal modulation. In fact we
demonstrated reduced HRV time and frequency domain
indices at day and night and an abnormal P2 during the
day only.
The association between PAD and autonomic neur-
opathy could be explained by the insulin resistance ob-
served in patients with type 2 diabetes. In The Edinburgh
Artery Study, a higher prevalence of PAD was observed
in patients with diabetes in comparison with those
without it, probably due to the higher systolic BP and
triglycerides observed in these patients, both variables
associated with insulin resistance [21]. Similarly, insulin
resistance has been associated with low HRV [22], re-
inforcing the idea that hyperinsulinemia could be asso-
ciated with an increased sympathetic tonus [23]. In the
present study, a higher prevalence of hypertension and
a larger waist-to-hip ratio were observed in patients with
PAD, parameters that have been associated with insulin
resistance. However, in the current study the association
of HRV abnormalities with PAD was independent of
blood pressure, as demonstrated in the multivariate
analyses. This result suggests a direct association of auto-
nomic dysfunction with PAD.
A relationship of atherosclerosis with autonomic car-
diovascular dysfunction has already been observed [24].
However, as far as we known, no study demonstrated the
association of PAD with CAN. The EURODIAB data
showed an association of low HDL cholesterol and high
triglycerides in patients with cardiovascular autonomic
neuropathy, suggesting a role for an adverse lipid profile
in the pathogenesis of CAN [25]. Autonomic neuropathy
was already related to lower-extremity arterial calcification
in type 1 diabetes [3]. In patients with type 2 diabetes
the LF index, a HRV parameter that reflects mainly sym-
pathetic modulation, predicted progression of carotid ath-
erosclerosis [7] and coronary artery disease [6,24,26]. None
of these studies evaluated the association of HRV abnor-
malities with PAD.
Possible limitations of the present study are related to
the accuracy of HRV indices to evaluate sympatheticmodulation. Maybe the use of controlled sympathetic
stimulation - as head up tilt or mental stress - could add
more information about the cardiac sympathetic modu-
lation in these patients. Another factor that could have
reduced the detection of HRV abnormalities in the current
study was the exclusion of patients with arrhythmias since
this group possibly had even lower HRV. However, despite
these methodological limitations, the consistent demon-
stration of differences in various HRV indices between
patients with and without PAD suggests that the results
of the present study are true.Conclusion
In this sample of patients with type 2 diabetes, those
with PAD had lower HRV indices than patients without
PAD, reflecting a dysfunction of cardiovascular autonomic
modulation. This impaired cardiac autonomic modulation
might represent an additional cardiovascular risk factor
for patients with type 2 diabetes and PAD. However, the
role of these abnormalities as predictors of mortality in
diabetic patients with PAD should be evaluated in pro-
spective studies.
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